Brain SPECT Imaging of Amphetamine-Induced Dopamine Release in Euthymic Bipolar Disorder Patients
OBJECTIVE: Increased dopaminergic neurotransmission has been implicated in the pathophysiology of bipolar disorder. However, it remains unclear whether the abnormality is due to increased dopamine release or enhanced postsynaptic receptor sensitivity. In this study, dopamine receptor imaging combine...
Saved in:
Published in | The American journal of psychiatry Vol. 157; no. 7; pp. 1108 - 1114 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
Washington, DC
American Psychiatric Publishing
01.07.2000
American Psychiatric Association |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | OBJECTIVE: Increased dopaminergic neurotransmission has been implicated in the pathophysiology of bipolar disorder. However, it remains unclear whether the abnormality is due to increased dopamine release or enhanced postsynaptic receptor sensitivity. In this study, dopamine receptor imaging combined with a pharmacological challenge of amphetamine was used to assess both pre- and postsynaptic aspects of dopamine neurotransmission in euthymic bipolar disorder patients.METHOD: Thirteen patients with bipolar disorder (seven medication free and six receiving mood stabilizer therapy) who had been euthymic for more than 4 weeks and 13 age- and gender-matched healthy comparison subjects were included in the study. Single photon emission computed tomography scans were obtained with the striatal dopamine (D2 D3) receptor radiotracer iodobenzamide ([123I]IBZM) before and after an intravenous amphetamine challenge (0.3 mg kg). Reduction in striatal [123I]IBZM binding potential from the first scan to the second scan was used as an indirect measure of the amount of dopamine released. Behavioral response to amphetamine was measured with the Brief Psychiatric Rating Scale, Young Mania Rating Scale, and visual analogue scales.RESULTS: Bipolar patients and healthy subjects did not differ in terms of mood state or striatal D2 receptor binding at baseline. Amphetamine challenge led to a significantly greater behavioral response in bipolar patients than in healthy subjects. However, there was no significant difference between the two groups in the amphetamine-induced decrease in striatal [123I]IBZM binding.CONCLUSIONS: In a group of euthymic patients with bipolar disorder, this study did not find evidence for increased striatal dopamine release. Instead, these data are consistent with enhanced postsynaptic dopamine responsivity in patients with bipolar disorder. |
---|---|
AbstractList | Increased dopaminergic neurotransmission has been implicated in the pathophysiology of bipolar disorder. However, it remains unclear whether the abnormality is due to increased dopamine release or enhanced postsynaptic receptor sensitivity. In this study, dopamine receptor imaging combined with a pharmacological challenge of amphetamine was used to assess both pre- and postsynaptic aspects of dopamine neurotransmission in euthymic bipolar disorder patients.
Thirteen patients with bipolar disorder (seven medication free and six receiving mood stabilizer therapy) who had been euthymic for more than 4 weeks and 13 age- and gender-matched healthy comparison subjects were included in the study. Single photon emission computed tomography scans were obtained with the striatal dopamine (D(2)/D(3)) receptor radiotracer iodobenzamide ([(123)I]IBZM) before and after an intravenous amphetamine challenge (0.3 mg/kg). Reduction in striatal [(123)I]IBZM binding potential from the first scan to the second scan was used as an indirect measure of the amount of dopamine released. Behavioral response to amphetamine was measured with the Brief Psychiatric Rating Scale, Young Mania Rating Scale, and visual analogue scales.
Bipolar patients and healthy subjects did not differ in terms of mood state or striatal D(2) receptor binding at baseline. Amphetamine challenge led to a significantly greater behavioral response in bipolar patients than in healthy subjects. However, there was no significant difference between the two groups in the amphetamine-induced decrease in striatal [(123)I]IBZM binding.
In a group of euthymic patients with bipolar disorder, this study did not find evidence for increased striatal dopamine release. Instead, these data are consistent with enhanced postsynaptic dopamine responsivity in patients with bipolar disorder. OBJECTIVE: Increased dopaminergic neurotransmission has been implicated in the pathophysiology of bipolar disorder. However, it remains unclear whether the abnormality is due to increased dopamine release or enhanced postsynaptic receptor sensitivity. In this study, dopamine receptor imaging combined with a pharmacological challenge of amphetamine was used to assess both pre- and postsynaptic aspects of dopamine neurotransmission in euthymic bipolar disorder patients.METHOD: Thirteen patients with bipolar disorder (seven medication free and six receiving mood stabilizer therapy) who had been euthymic for more than 4 weeks and 13 age- and gender-matched healthy comparison subjects were included in the study. Single photon emission computed tomography scans were obtained with the striatal dopamine (D2 D3) receptor radiotracer iodobenzamide ([123I]IBZM) before and after an intravenous amphetamine challenge (0.3 mg kg). Reduction in striatal [123I]IBZM binding potential from the first scan to the second scan was used as an indirect measure of the amount of dopamine released. Behavioral response to amphetamine was measured with the Brief Psychiatric Rating Scale, Young Mania Rating Scale, and visual analogue scales.RESULTS: Bipolar patients and healthy subjects did not differ in terms of mood state or striatal D2 receptor binding at baseline. Amphetamine challenge led to a significantly greater behavioral response in bipolar patients than in healthy subjects. However, there was no significant difference between the two groups in the amphetamine-induced decrease in striatal [123I]IBZM binding.CONCLUSIONS: In a group of euthymic patients with bipolar disorder, this study did not find evidence for increased striatal dopamine release. Instead, these data are consistent with enhanced postsynaptic dopamine responsivity in patients with bipolar disorder. Increased dopaminergic neutotransmission has been implicated in the pathophysiology of bipolar disorder. However, it remains unclear whether the abnormality is due to increased dopamine release or enhanced postsynaptic receptor sensitivity. Increased dopaminergic neurotransmission has been implicated in the pathophysiology of bipolar disorder. However, it remains unclear whether the abnormality is due to increased dopamine release or enhanced postsynaptic receptor sensitivity. In this study, dopamine receptor imaging combined with a pharmacological challenge of amphetamine was used to assess both pre- and postsynaptic aspects of dopamine neurotransmission in euthymic bipolar disorder patients.OBJECTIVEIncreased dopaminergic neurotransmission has been implicated in the pathophysiology of bipolar disorder. However, it remains unclear whether the abnormality is due to increased dopamine release or enhanced postsynaptic receptor sensitivity. In this study, dopamine receptor imaging combined with a pharmacological challenge of amphetamine was used to assess both pre- and postsynaptic aspects of dopamine neurotransmission in euthymic bipolar disorder patients.Thirteen patients with bipolar disorder (seven medication free and six receiving mood stabilizer therapy) who had been euthymic for more than 4 weeks and 13 age- and gender-matched healthy comparison subjects were included in the study. Single photon emission computed tomography scans were obtained with the striatal dopamine (D(2)/D(3)) receptor radiotracer iodobenzamide ([(123)I]IBZM) before and after an intravenous amphetamine challenge (0.3 mg/kg). Reduction in striatal [(123)I]IBZM binding potential from the first scan to the second scan was used as an indirect measure of the amount of dopamine released. Behavioral response to amphetamine was measured with the Brief Psychiatric Rating Scale, Young Mania Rating Scale, and visual analogue scales.METHODThirteen patients with bipolar disorder (seven medication free and six receiving mood stabilizer therapy) who had been euthymic for more than 4 weeks and 13 age- and gender-matched healthy comparison subjects were included in the study. Single photon emission computed tomography scans were obtained with the striatal dopamine (D(2)/D(3)) receptor radiotracer iodobenzamide ([(123)I]IBZM) before and after an intravenous amphetamine challenge (0.3 mg/kg). Reduction in striatal [(123)I]IBZM binding potential from the first scan to the second scan was used as an indirect measure of the amount of dopamine released. Behavioral response to amphetamine was measured with the Brief Psychiatric Rating Scale, Young Mania Rating Scale, and visual analogue scales.Bipolar patients and healthy subjects did not differ in terms of mood state or striatal D(2) receptor binding at baseline. Amphetamine challenge led to a significantly greater behavioral response in bipolar patients than in healthy subjects. However, there was no significant difference between the two groups in the amphetamine-induced decrease in striatal [(123)I]IBZM binding.RESULTSBipolar patients and healthy subjects did not differ in terms of mood state or striatal D(2) receptor binding at baseline. Amphetamine challenge led to a significantly greater behavioral response in bipolar patients than in healthy subjects. However, there was no significant difference between the two groups in the amphetamine-induced decrease in striatal [(123)I]IBZM binding.In a group of euthymic patients with bipolar disorder, this study did not find evidence for increased striatal dopamine release. Instead, these data are consistent with enhanced postsynaptic dopamine responsivity in patients with bipolar disorder.CONCLUSIONSIn a group of euthymic patients with bipolar disorder, this study did not find evidence for increased striatal dopamine release. Instead, these data are consistent with enhanced postsynaptic dopamine responsivity in patients with bipolar disorder. |
Author | Anand, Amit Zoghbi, Sami S. Charney, Dennis S. Seneca, Nicholas Seibyl, John P. Verhoeff, Paul Innis, Robert B. |
Author_xml | – sequence: 1 givenname: Amit surname: Anand fullname: Anand, Amit – sequence: 2 givenname: Paul surname: Verhoeff fullname: Verhoeff, Paul – sequence: 3 givenname: Nicholas surname: Seneca fullname: Seneca, Nicholas – sequence: 4 givenname: Sami S. surname: Zoghbi fullname: Zoghbi, Sami S. – sequence: 5 givenname: John P. surname: Seibyl fullname: Seibyl, John P. – sequence: 6 givenname: Dennis S. surname: Charney fullname: Charney, Dennis S. – sequence: 7 givenname: Robert B. surname: Innis fullname: Innis, Robert B. |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1437720$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/10873919$$D View this record in MEDLINE/PubMed |
BookMark | eNqFkU1v1DAQhi1URLeFX4CELEDcsvhjE8fHdrvASpWooEjcrFnHab1K7NRODv33zHYXFVUCTrZnnnfGM-8JOQoxOEJeczbnXFUfYRj8HLbDnJdqrjDG6mdkxktZFkqI-ojMGGOi0KX8eUxOct7ik0klXpBjRJXUXM8InCfwgX6_Wi2v6bqHGx9uaGzpWT_cuhF6H1yxDs1kXUMv4vAQoN9c5yA7isLVNN7e997Scz_EDhK98DmmxiV6BaN3YcwvyfMWuuxeHc5T8uPT6nr5pbj8-nm9PLssYKHFWGzkxuq6EWXZgmS1VYJBJZpaO2CV3lSYd7Vs8WZFI5QSoHGIDWhQoJTm8pR82NcdUrybXB5N77N1XQfBxSkbxYUQrNYIvn0CbuOUAv7NILAo9UIqhN79DeIlr6WuFpoh9eZATZveNWZIvod0b37vF4H3BwCyha5NEKzPjxy2wkERk3vMpphzcu0flczObLMz26DZ2F0ZZXZmo0o_UVk_4tZjGNHU7j9attc-JB9n-4fkF30Dv2Q |
CODEN | AJPSAO |
CitedBy_id | crossref_primary_10_1097_HRP_0000000000000003 crossref_primary_10_1016_j_pnpbp_2007_02_005 crossref_primary_10_1176_appi_ajp_159_10_1718 crossref_primary_10_1016_j_biopsych_2010_06_005 crossref_primary_10_1097_00004647_200303000_00004 crossref_primary_10_1111_j_1749_6632_2003_tb07095_x crossref_primary_10_1111_j_1468_2850_2009_01166_x crossref_primary_10_1016_j_biopsych_2005_11_006 crossref_primary_10_1300_J374v01n03_03 crossref_primary_10_1080_15332985_2011_639928 crossref_primary_10_1016_j_bpsc_2024_07_011 crossref_primary_10_1016_j_cpr_2008_04_004 crossref_primary_10_1111_bdi_12009 crossref_primary_10_1007_s11064_008_9865_8 crossref_primary_10_1007_s00441_013_1594_x crossref_primary_10_1177_070674370104600524 crossref_primary_10_1515_REVNEURO_2009_20_2_111 crossref_primary_10_1016_j_bbr_2009_06_009 crossref_primary_10_1016_j_neuint_2013_02_001 crossref_primary_10_1586_ern_12_64 crossref_primary_10_1038_sj_mp_4002135 crossref_primary_10_1097_01_WCB_0000048520_34839_1A crossref_primary_10_1111_jnc_13769 crossref_primary_10_1097_00001504_200105000_00011 crossref_primary_10_1016_j_neuropsychologia_2011_06_008 crossref_primary_10_1111_bdi_12251 crossref_primary_10_1016_j_neuroscience_2014_11_059 crossref_primary_10_1016_j_pscychresns_2011_04_002 crossref_primary_10_1212_01_wnl_0000341932_21961_f3 crossref_primary_10_1007_s00702_009_0198_9 crossref_primary_10_1176_ajp_2006_163_6_1112a crossref_primary_10_1016_j_brainresrev_2008_07_006 crossref_primary_10_1001_jamapsychiatry_2017_2943 crossref_primary_10_1080_1028415X_2024_2338344 crossref_primary_10_1038_mp_2016_261 crossref_primary_10_1002_syn_20013 crossref_primary_10_1016_j_neulet_2011_05_027 crossref_primary_10_1111_j_1600_0447_2007_01058_x crossref_primary_10_1016_j_lfs_2006_01_002 crossref_primary_10_1016_S1566_2772_02_00043_9 crossref_primary_10_1016_j_euroneuro_2022_08_006 crossref_primary_10_1016_j_jad_2004_11_009 crossref_primary_10_1111_j_1399_5618_2011_00936_x crossref_primary_10_1192_j_eurpsy_2021_1 crossref_primary_10_1186_s12974_018_1283_5 crossref_primary_10_1016_j_jpsychires_2007_03_005 crossref_primary_10_1176_appi_ajp_2012_11101585 crossref_primary_10_1016_j_jad_2021_08_022 crossref_primary_10_1007_s00213_021_05960_2 crossref_primary_10_1007_s11011_013_9473_4 crossref_primary_10_1016_j_genhosppsych_2010_11_005 crossref_primary_10_1111_j_1399_5618_2005_00211_x crossref_primary_10_1002_syn_20062 crossref_primary_10_1017_S146114571000101X crossref_primary_10_1038_sj_mp_4001547 crossref_primary_10_1038_mp_2009_39 crossref_primary_10_1196_annals_1417_000 crossref_primary_10_1111_j_1399_5618_2007_00354_x crossref_primary_10_1038_sj_mp_4001020 crossref_primary_10_1016_j_neubiorev_2006_12_001 crossref_primary_10_2116_analsci_19_67 crossref_primary_10_1073_pnas_1108416108 crossref_primary_10_1034_j_1399_5618_2001_030201_x crossref_primary_10_1038_sj_npp_1301254 crossref_primary_10_1001_jamapsychiatry_2024_4216 crossref_primary_10_1002_syn_20238 crossref_primary_10_1007_s11064_008_9595_y crossref_primary_10_1017_S1461145710001495 crossref_primary_10_1016_S0376_8716_00_00240_4 crossref_primary_10_1007_s00213_019_05295_z crossref_primary_10_1016_j_psym_2012_01_005 crossref_primary_10_1176_appi_ajp_159_5_768 crossref_primary_10_1016_j_nucmedbio_2005_01_007 crossref_primary_10_1016_j_pnpbp_2003_10_015 crossref_primary_10_1046_j_1601_5215_2003_00053_x crossref_primary_10_1111_1440_1681_13243 crossref_primary_10_1111_j_1399_5618_2010_00874_x crossref_primary_10_1016_j_euroneuro_2008_11_002 crossref_primary_10_1016_j_childyouth_2010_03_021 crossref_primary_10_3390_biomedicines11071820 crossref_primary_10_1111_j_1399_5618_2009_00760_x crossref_primary_10_1016_j_bbr_2019_01_006 crossref_primary_10_1016_j_brainres_2008_10_023 crossref_primary_10_1177_0891988713516540 crossref_primary_10_1176_appi_ajp_160_1_13 crossref_primary_10_1186_1471_244X_4_27 crossref_primary_10_1016_j_nbd_2010_08_005 crossref_primary_10_1146_annurev_clinpsy_2_022305_095332 crossref_primary_10_1186_1866_1955_4_19 crossref_primary_10_1007_s11682_016_9516_7 crossref_primary_10_1111_j_1399_5618_2009_00771_x crossref_primary_10_1590_1516_4446_2013_1168 crossref_primary_10_1016_j_psc_2011_02_010 crossref_primary_10_1080_14737175_2020_1807329 crossref_primary_10_1111_j_1601_5215_2004_0061_x crossref_primary_10_1002_ajmg_10360 crossref_primary_10_1016_j_bbr_2012_03_021 crossref_primary_10_1038_sj_npp_1300665 crossref_primary_10_1080_1029842021000022070 crossref_primary_10_1080_j_1440_1614_2006_01805_x crossref_primary_10_1016_j_neuropharm_2011_07_025 crossref_primary_10_1038_mp_2010_3 crossref_primary_10_1111_bdi_12299 crossref_primary_10_1177_0269881106073126 crossref_primary_10_1007_s12035_019_01817_0 crossref_primary_10_1146_annurev_clinpsy_032511_143148 crossref_primary_10_1111_j_1399_5618_2004_00110_x crossref_primary_10_1007_s10519_006_9093_4 crossref_primary_10_1016_j_ejphar_2014_05_063 crossref_primary_10_1016_S0006_3223_01_01089_7 crossref_primary_10_1177_0269881105051525 crossref_primary_10_1016_j_jad_2011_02_022 crossref_primary_10_1002_syn_10010 crossref_primary_10_1111_j_1460_9568_2004_03199_x crossref_primary_10_1111_j_1440_1614_2006_01805_x crossref_primary_10_1093_schbul_sbr180 crossref_primary_10_1016_j_neubiorev_2007_04_002 crossref_primary_10_1038_sj_mp_4001585 crossref_primary_10_1007_s12035_016_9933_z crossref_primary_10_1159_000480349 crossref_primary_10_1177_0269881114523864 crossref_primary_10_1016_j_pnpbp_2006_03_016 crossref_primary_10_1002_cpp_1801 crossref_primary_10_1016_j_pbb_2010_11_004 crossref_primary_10_1080_09540260902962131 crossref_primary_10_1017_S1092852900009238 crossref_primary_10_1038_sj_npp_1301333 crossref_primary_10_1002_wps_21080 crossref_primary_10_1038_mp_2017_16 crossref_primary_10_1097_00019442_200211000_00010 crossref_primary_10_1111_j_1749_6632_2009_05146_x crossref_primary_10_1016_j_neubiorev_2010_04_002 crossref_primary_10_1016_j_lfs_2007_11_026 crossref_primary_10_1016_S0163_8343_01_00135_9 crossref_primary_10_1586_14737175_2013_811132 crossref_primary_10_2217_npy_11_69 crossref_primary_10_1016_j_pnpbp_2008_09_017 crossref_primary_10_1016_j_jpsychires_2024_12_046 crossref_primary_10_1111_gbb_12371 crossref_primary_10_1097_WNF_0b013e31816f75bc |
Cites_doi | 10.1016/0969-8051(94)90087-6 10.1055/s-2007-1019521 10.2466/pr0.1962.10.3.799 10.1176/ajp.155.6.761 10.1111/j.1471-4159.1993.tb03600.x 10.1046/j.1471-4159.1998.70041768.x 10.1017/S0033291700009132 10.1176/ajp.156.9.1440 10.1192/bjp.133.5.429 10.1016/S0006-3223(99)00067-0 10.1002/syn.890100302 10.1002/syn.890070409 10.1001/archpsyc.1995.03950180057008 10.1016/0006-3223(95)00611-7 10.1073/pnas.93.17.9235 10.1007/BF00428897 10.1002/hbm.460030303 |
ContentType | Journal Article |
Copyright | 2000 INIST-CNRS Copyright American Psychiatric Association Jul 2000 |
Copyright_xml | – notice: 2000 INIST-CNRS – notice: Copyright American Psychiatric Association Jul 2000 |
DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM HAWNG HBMBR IBDFT K30 PAAUG PAWHS PAWZZ PAXOH PBHAV PBQSW PBYQZ PCIWU PCMID PCZJX PDGRG PDWWI PETMR PFVGT PGXDX PIHIL PISVA PJCTQ PJTMS PLCHJ PMHAD PNQDJ POUND PPLAD PQAPC PQCAN PQCMW PQEME PQHKH PQMID PQNCT PQNET PQSCT PQSET PSVJG PVMQY PZGFC K9. NAPCQ 7X8 |
DOI | 10.1176/appi.ajp.157.7.1108 |
DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Periodicals Index Online Segment 13 Periodicals Index Online Segment 14 Periodicals Index Online Segment 27 Periodicals Index Online Primary Sources Access—Foundation Edition (Plan E) - West Primary Sources Access (Plan D) - International Primary Sources Access & Build (Plan A) - MEA Primary Sources Access—Foundation Edition (Plan E) - Midwest Primary Sources Access—Foundation Edition (Plan E) - Northeast Primary Sources Access (Plan D) - Southeast Primary Sources Access (Plan D) - North Central Primary Sources Access—Foundation Edition (Plan E) - Southeast Primary Sources Access (Plan D) - South Central Primary Sources Access & Build (Plan A) - UK / I Primary Sources Access (Plan D) - Canada Primary Sources Access (Plan D) - EMEALA Primary Sources Access—Foundation Edition (Plan E) - North Central Primary Sources Access—Foundation Edition (Plan E) - South Central Primary Sources Access & Build (Plan A) - International Primary Sources Access—Foundation Edition (Plan E) - International Primary Sources Access (Plan D) - West Periodicals Index Online Segments 1-50 Primary Sources Access (Plan D) - APAC Primary Sources Access (Plan D) - Midwest Primary Sources Access (Plan D) - MEA Primary Sources Access—Foundation Edition (Plan E) - Canada Primary Sources Access—Foundation Edition (Plan E) - UK / I Primary Sources Access—Foundation Edition (Plan E) - EMEALA Primary Sources Access & Build (Plan A) - APAC Primary Sources Access & Build (Plan A) - Canada Primary Sources Access & Build (Plan A) - West Primary Sources Access & Build (Plan A) - EMEALA Primary Sources Access (Plan D) - Northeast Primary Sources Access & Build (Plan A) - Midwest Primary Sources Access & Build (Plan A) - North Central Primary Sources Access & Build (Plan A) - Northeast Primary Sources Access & Build (Plan A) - South Central Primary Sources Access & Build (Plan A) - Southeast Primary Sources Access (Plan D) - UK / I Primary Sources Access—Foundation Edition (Plan E) - APAC Primary Sources Access—Foundation Edition (Plan E) - MEA ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Periodicals Index Online Segment 14 Periodicals Index Online Segments 1-50 Periodicals Index Online Segment 27 Periodicals Index Online Periodicals Index Online Segment 13 ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium MEDLINE - Academic |
DatabaseTitleList | MEDLINE ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1535-7228 |
EndPage | 1114 |
ExternalDocumentID | 56323420 10873919 1437720 10_1176_appi_ajp_157_7_1108 10.1176/appi.ajp.157.7.1108 |
Genre | Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S Journal Article |
GrantInformation_xml | – fundername: NCRR NIH HHS grantid: RR-00125 – fundername: NIMH NIH HHS grantid: MH-30929 |
GroupedDBID | --- --Z -DZ -~X .55 .GJ 0WA 1HT 1KJ 1QT 23M 2WC 3O- 4.4 53G 5GY 5RE 6J9 6TJ 7K8 85S 8R4 8R5 AAAHA AAIKC AAMNW AAWTL AAWTO ABIVO ABPPZ ABZEH ACBMB ACGFO ACGOD ACHQT ACNCT ADBBV ADCOW AENEX AETEA AFAZI AFFNX AFMIJ AFOSN AGHSJ AGNAY AHJKT AHMBA AI. AIZTS ALMA_UNASSIGNED_HOLDINGS ASUFR BAJDF BAWUL BENPR BKOMP CS3 DIK E3Z EBS EJD EX3 F20 F5P F8P FA8 FJW G0H G8K HF~ HZ~ J5H L7B MVM N4W N9A NEJ NHB OHT OK1 OVD P-O P2P PQQKQ Q.- Q2X RAY RWL RXW RYA S10 SJN SKT TAE TEORI TR2 TWZ UHB UKR ULE UPT UQL VH1 VVN WH7 WHG WOQ WOW X4V X6Y X7M XJT XOL XSW XZL YCJ YFH YOC YSK YWH YZZ ZCA ZGI ZRR ZXP ZY1 ~A~ ~G0 AAJMC AAYXX ABDPE ADMHG CITATION H13 08P 08R 1CY 2QL 354 41~ 8F7 AAJWC AAKAS AAPBV AAQQT AAUGY AAYJJ ABPTK ADZCM AERZD AFFDN AKALU BCR BLC GOZPB GRPMH IQODW LXL LXN PEA UBC YQI YQJ YRY YXB YYQ ZA5 ZHY ZKB ~X8 CGR CUY CVF ECM EIF LPU NPM VXZ YIF YIN Z5M HAWNG HBMBR IBDFT K30 PAAUG PAWHS PAWZZ PAXOH PBHAV PBQSW PBYQZ PCIWU PCMID PCZJX PDGRG PDWWI PETMR PFVGT PGXDX PIHIL PISVA PJCTQ PJTMS PLCHJ PMHAD PNQDJ POUND PPLAD PQAPC PQCAN PQCMW PQEME PQHKH PQMID PQNCT PQNET PQSCT PQSET PSVJG PVMQY PZGFC ADXHL K9. NAPCQ 7X8 |
ID | FETCH-LOGICAL-a492t-b3bc98d255fa308c720a62d89ea069b6b3be83f9b6c2d2772a9087ba9a7a77913 |
ISSN | 0002-953X |
IngestDate | Fri Jul 11 01:45:04 EDT 2025 Fri Aug 22 03:12:36 EDT 2025 Mon Jun 30 16:06:04 EDT 2025 Wed Feb 19 01:45:11 EST 2025 Sun Oct 22 16:07:12 EDT 2023 Tue Jul 01 01:51:18 EDT 2025 Thu Apr 24 22:59:20 EDT 2025 Wed Jul 24 08:11:01 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 7 |
Keywords | Radionuclide study Mood disorder Amphetamine derivatives Human Dopamine Pathophysiology Induction Central nervous system Bipolar disorder Photon Dopaminergic transmission Biological fixation D2 Dopamine receptor Amfetamine Clinical investigation Computer aid Release Brain (vertebrata) Emission tomography |
Language | English |
License | CC BY 4.0 |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-a492t-b3bc98d255fa308c720a62d89ea069b6b3be83f9b6c2d2772a9087ba9a7a77913 |
Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 14 ObjectType-Article-1 ObjectType-Feature-2 content type line 23 |
PMID | 10873919 |
PQID | 1518396490 |
PQPubID | 1816671 |
PageCount | 7 |
ParticipantIDs | proquest_miscellaneous_71222089 proquest_journals_220459437 proquest_journals_1518396490 pubmed_primary_10873919 pascalfrancis_primary_1437720 crossref_primary_10_1176_appi_ajp_157_7_1108 crossref_citationtrail_10_1176_appi_ajp_157_7_1108 appi_journals_10_1176_appi_ajp_157_7_1108 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2000-07-01 |
PublicationDateYYYYMMDD | 2000-07-01 |
PublicationDate_xml | – month: 07 year: 2000 text: 2000-07-01 day: 01 |
PublicationDecade | 2000 |
PublicationPlace | Washington, DC |
PublicationPlace_xml | – name: Washington, DC – name: United States – name: Washington, D.C – name: Washington |
PublicationTitle | The American journal of psychiatry |
PublicationTitleAlternate | Am J Psychiatry |
PublicationYear | 2000 |
Publisher | American Psychiatric Publishing American Psychiatric Association |
Publisher_xml | – name: American Psychiatric Publishing – name: American Psychiatric Association |
References | R1577CIHJIEJF R1577CIHIGIAE R1577CIHGAFIJ R1577CIHBJCIG R1577CIHCFHFF R1577CIHCEDDJ R1577CIHBGAGE R1577CIHFJCCA R1577CIHHGIGB R1577CIHIJFFD R1577CIHBFEEA R1577CIHBCAEF R1577CIHCAFHG R1577CIHGGIHG R1577CIHBADHE R1577CIHGDEAB R1577CIHIGHHC R1577CIHEGBBA |
References_xml | – ident: R1577CIHCEDDJ doi: 10.1016/0969-8051(94)90087-6 – ident: R1577CIHBJCIG – ident: R1577CIHBCAEF doi: 10.1055/s-2007-1019521 – ident: R1577CIHCFHFF doi: 10.2466/pr0.1962.10.3.799 – ident: R1577CIHJIEJF doi: 10.1176/ajp.155.6.761 – ident: R1577CIHBGAGE doi: 10.1111/j.1471-4159.1993.tb03600.x – ident: R1577CIHCAFHG doi: 10.1046/j.1471-4159.1998.70041768.x – ident: R1577CIHIJFFD doi: 10.1017/S0033291700009132 – ident: R1577CIHEGBBA doi: 10.1176/ajp.156.9.1440 – ident: R1577CIHGAFIJ doi: 10.1192/bjp.133.5.429 – ident: R1577CIHGDEAB doi: 10.1016/S0006-3223(99)00067-0 – ident: R1577CIHIGHHC doi: 10.1002/syn.890100302 – ident: R1577CIHIGIAE doi: 10.1002/syn.890070409 – ident: R1577CIHBFEEA doi: 10.1001/archpsyc.1995.03950180057008 – ident: R1577CIHGGIHG doi: 10.1016/0006-3223(95)00611-7 – ident: R1577CIHHGIGB doi: 10.1073/pnas.93.17.9235 – ident: R1577CIHBADHE doi: 10.1007/BF00428897 – ident: R1577CIHFJCCA doi: 10.1002/hbm.460030303 |
SSID | ssj0000372 |
Score | 2.0943065 |
Snippet | OBJECTIVE: Increased dopaminergic neurotransmission has been implicated in the pathophysiology of bipolar disorder. However, it remains unclear whether the... Increased dopaminergic neurotransmission has been implicated in the pathophysiology of bipolar disorder. However, it remains unclear whether the abnormality is... Increased dopaminergic neutotransmission has been implicated in the pathophysiology of bipolar disorder. However, it remains unclear whether the abnormality is... |
SourceID | proquest pubmed pascalfrancis crossref appi |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 1108 |
SubjectTerms | Adult Adult and adolescent clinical studies Amphetamine - pharmacology Amphetamines Benzamides - metabolism Biological and medical sciences Bipolar Disorder - diagnostic imaging Bipolar Disorder - metabolism Bipolar Disorder - physiopathology Bipolar disorders Blood Pressure - drug effects Brain Brain - diagnostic imaging Brain - metabolism Brain - physiopathology Corpus Striatum - diagnostic imaging Corpus Striatum - metabolism Corpus Striatum - physiopathology Dopamine - metabolism Dopamine Antagonists - metabolism Female Heart Rate - drug effects Humans Iodine Radioisotopes - metabolism Male Manic depression Medical imaging Medical sciences Mental disorders Mood disorders Neurotransmitters Psychology. Psychoanalysis. Psychiatry Psychopathology. Psychiatry Pulse Pyrrolidines - metabolism Receptors, Dopamine - drug effects Receptors, Dopamine - metabolism Tomography, Emission-Computed, Single-Photon |
Title | Brain SPECT Imaging of Amphetamine-Induced Dopamine Release in Euthymic Bipolar Disorder Patients |
URI | http://dx.doi.org/10.1176/appi.ajp.157.7.1108 https://www.ncbi.nlm.nih.gov/pubmed/10873919 https://www.proquest.com/docview/1518396490 https://www.proquest.com/docview/220459437 https://www.proquest.com/docview/71222089 |
Volume | 157 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELagSAgJId6EtuADF1SyZONsHB-hKiqgIqTdoopL5DgOW8QmUTd74dcz49h5wLYCLlHkiRPL35fJTOyZIeQF05HOBct9yUXgRzqc-kkhM1_luQK8VcAkxjuffIqPT6MPZ7Ozfq-qiS5pson6uTWu5H9QhTbAFaNk_wHZ7qbQAOeALxwBYTj-FcZvsb7Dwfzz0eHi4Hxl6w1hAaF6qRu5AgPSB5d7g0v8OTjH2GCKpMCXy6QK2QBKuDc-O6_Rw8XVGpOK02VbXQ9N10Ufg1IOE06M90u3vxTcbknX8kVfLCvdJoDsAsrmoGaVHC0Hfa2-LTOzv2Bu_8m6HxJBt3l1qGTFzJT57ZVsm4basokPVCbGIWzX5dwkMa4xpu97PYE7TPjk96sBkHpl4AUBZ8Lq33EKbSe6Tm6E4E0Yz_v9x_6DzXjovCQct01OBc9_veXpmGbW3g8-43jByKS5Xcs1vF1FWxblcr_F2C-Lu-SOdTzom5ZF98g1Xd4nN0_s1ooHRBoyUUMmaslEq4JuIRN1ZKKWTBQ6OjJRSybqyEQdmR6S03dHi8Nj39bf8GUkwsbPWKZEkoPTWUgWJIqHgYzDPBFaBrHIYpDrhBVwpsIcJ1YKmJhMCskl52LKHpGdsir1E0J5kcRoCapYRRHjkShC0B2iyKXSQZFMPfISZzK17F2nxjflcWpaAYAUAEh5igB4JHTTnSqbyB7rqfy4utOrrlPd5nG5-vL9EY59Hxg9zINH9hyugzHP0N2IIwHi3T_FIVZ-ENDfI887KShzXKGTpa4265RPwVwPEuGRxy1XBmNtKff0UskuudW_jXtkp7nY6H0wmJvsmaH7L4kqvzM |
linkProvider | Flying Publisher |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Brain+SPECT+imaging+of+amphetamine-induced+dopamine+release+in+euthymic+bipolar+disorder+patients&rft.jtitle=The+American+journal+of+psychiatry&rft.au=Anand%2C+A&rft.au=Verhoeff%2C+P&rft.au=Seneca%2C+N&rft.au=Zoghbi%2C+S+S&rft.date=2000-07-01&rft.issn=0002-953X&rft.volume=157&rft.issue=7&rft.spage=1108&rft_id=info:doi/10.1176%2Fappi.ajp.157.7.1108&rft_id=info%3Apmid%2F10873919&rft.externalDocID=10873919 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0002-953X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0002-953X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0002-953X&client=summon |